Insider Buying: KalVista Pharmaceuticals, Inc. (NASDAQ:KALV) Major Shareholder Purchases 14,562 Shares of Stock

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) major shareholder Venrock Healthcare Capital Par purchased 14,562 shares of the firm's stock in a transaction dated Monday, February 3rd. The stock was purchased at an average cost of $9.22 per share, with a total value of $134,261.64. Following the acquisition, the insider now directly owns 5,012,796 shares in the company, valued at $46,217,979.12. This trade represents a 0.29 % increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Major shareholders that own 10% or more of a company's stock are required to disclose their transactions with the SEC.

Venrock Healthcare Capital Par also recently made the following trade(s):

• On Thursday, January 30th, Venrock Healthcare Capital Par purchased 43,707 shares of KalVista Pharmaceuticals stock. The shares were acquired at an average cost of $8.76 per share, for a total transaction of $382,873.32.

KalVista Pharmaceuticals Stock Performance

KALV traded down $0.42 during trading hours on Friday, reaching $9.20. The company's stock had a trading volume of 303,808 shares, compared to its average volume of 293,376. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.88. The firm has a market cap of $454.66 million, a PE ratio of -2.53 and a beta of 0.85. The company's 50-day moving average is $8.80 and its 200-day moving average is $10.76.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its earnings results on Thursday, December 5th. The specialty pharmaceutical company reported ($0.91) EPS for the quarter, beating the consensus estimate of ($0.92) by $0.01. Equities analysts anticipate that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on KALV shares. TD Cowen assumed coverage on shares of KalVista Pharmaceuticals in a research report on Tuesday, January 7th. They set a "buy" rating and a $30.00 price objective for the company. Needham & Company LLC restated a "buy" rating and issued a $28.00 price target on shares of KalVista Pharmaceuticals in a report on Thursday, December 5th. HC Wainwright reiterated a "buy" rating and issued a $20.00 price target on shares of KalVista Pharmaceuticals in a research note on Friday, December 6th. JMP Securities initiated coverage on shares of KalVista Pharmaceuticals in a research note on Friday, January 31st. They set an "outperform" rating and a $19.00 price objective for the company. Finally, Bank of America began coverage on KalVista Pharmaceuticals in a research note on Wednesday, December 18th. They set a "buy" rating and a $22.00 price objective on the stock. Six equities research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat, the company has an average rating of "Buy" and a consensus target price of $23.80.

Institutional Investors Weigh In On KalVista Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. China Universal Asset Management Co. Ltd. increased its position in KalVista Pharmaceuticals by 24.7% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 10,329 shares of the specialty pharmaceutical company's stock worth $87,000 after acquiring an additional 2,043 shares during the period. SG Americas Securities LLC grew its position in shares of KalVista Pharmaceuticals by 10.0% during the 4th quarter. SG Americas Securities LLC now owns 14,508 shares of the specialty pharmaceutical company's stock worth $123,000 after purchasing an additional 1,319 shares in the last quarter. Intech Investment Management LLC acquired a new position in shares of KalVista Pharmaceuticals during the 3rd quarter worth approximately $126,000. AlphaQuest LLC increased its holdings in shares of KalVista Pharmaceuticals by 17.1% during the fourth quarter. AlphaQuest LLC now owns 17,700 shares of the specialty pharmaceutical company's stock worth $150,000 after purchasing an additional 2,588 shares during the period. Finally, Quest Partners LLC bought a new stake in shares of KalVista Pharmaceuticals in the third quarter valued at approximately $175,000.

About KalVista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).